BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company incubated by Roivant Sciences (Nasdaq: ROIV), today announced the formation of its Scientific Advisory Board (SAB). Covant uses its unprecedented high-throughput chemoproteomics platform to discover novel small molecule therapeutics against hard-to-drug immunology and oncology targets.
“This is a very exciting time for Covant as we continue to build our compelling pipeline of therapeutic programs,” said Dr. Ivan Cornella, Chief Scientific Officer of Covant. “I am thrilled to welcome our new Scientific Advisory Board members. I believe that each of them is positioned to contribute significantly to Covant’s success in bringing novel covalent therapeutics to patients.”
The founding members of Covant’s SAB are:
About Covant Therapeutics
Covant Therapeutics is a Boston-based covalent drug discovery company that was incubated by Roivant Sciences (NASDAQ: ROIV). Covant creates novel therapeutics by using covalency to imprint and regulate proteins. To discover these therapeutics, the company applies cutting-edge capabilities and expertise in chemistry, quantitative proteomics, translational sciences, and deep learning. For more information, please visit www.covanttx.com.
Contacts
Investors
Covant Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Covant Public Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$11.91 |
Daily Change: | 0.03 0.25 |
Daily Volume: | 3,252,899 |
Market Cap: | US$8.810B |
September 18, 2024 September 10, 2024 September 10, 2024 September 09, 2024 August 08, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB